Lichen Planus Market

• The Lichen Planus Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• According to the findings, Lichen Planus is a chronic disease affecting the skin, appendages, and mucous membranes. It is a relatively common papulosquamous disorder of unknown etiology. The highest incidence is observed in patients of age 30 to 60 years.
• There is currently no standard-of-care or FDA-approved therapy for oral Lichen Planus, a disease that affects over 6 million Americans.
• The efficacy of commonly used treatments, such as topical and systemic steroids and steroid-sparing agents, is only partially effective.
• The pipeline for new treatments is not very extensive. LP-310, developed by Lipella Pharmaceuticals, is one of the few emerging therapies in this area.
• Lichen Planus companies are driving innovation in treatments for this chronic inflammatory skin condition. Key Lichen Planus players include Bristol Myers Squibb, Pfizer, Teva Pharmaceutical Industries, Mylan, and others.
• In February 2025, Onc.AI announced that the FDA has granted Breakthrough Device Designation for its "Serial CTRS" AI model. This AI-driven tool uses deep learning to analyze CT scans and categorize patients into high- or low-mortality risk groups.
• In February 2025, Lipella Pharmaceuticals (Nasdaq: LIPO) announced FDA approval for an Expanded Access Program (EAP) for LP-310, an oral rinse aimed at treating oral Lichen Planus (OLP).

DelveInsight's “Lichen Planus Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Lichen Planus, historical and forecasted epidemiology as well as the Lichen Planus therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Lichen Planus  market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Lichen Planus  market size from 2020 to 2034. The report also covers current Lichen Planus  treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Lichen Planus Treatment Market

Lichen Planus  Overview, Country-Specific Treatment Guidelines and Diagnosis

Lichen Planus is an inflammatory disorder of the skin and mucous membranes with no known cause. It appears as pruritic, violaceous papules and plaques most commonly found on the wrists, lower back, and ankles. A lattice-like network of white lines called Wickham striae overlies the lesions but is most easily observed on the buccal mucosa where erosions can also be present.

Lichen Planus is a chronic inflammatory condition affecting the skin and mucosal surfaces. There are several clinical types:

• Cutaneous Lichen Planus
• Mucosal Lichen Planus- oral, vulval/penile, or other sites.
• Lichen planopilaris
• Lichen Planus of the nails
• Lichen Planus pigmentosus
• Lichenoid drug eruption.

Drug-induced Lichen Planus, or lichenoid drug eruption, is frequently photo distributed but may be indistinguishable from idiopathic Lichen Planus. The natural history of Lichen Planus varies significantly. The majority of patients with cutaneous lesions spontaneously clear within 1 to 2 years after initial presentation. 

Lichen Planus can also display a variety of lesion types, but the most common presentation is an area of polygon-shaped, itchy, violaceous, flat-topped papules a few millimeters wide. Lichen Planus clinical trials are advancing innovative therapies, aiming to improve treatment outcomes and patient quality of life. Ongoing studies explore promising drugs and novel approaches for this chronic inflammatory condition.

Skin biopsy and microscopic analysis are valuable in confirming the diagnosis in atypical and severe cases as the histopathologic features are largely the same regardless of the distribution or subtype.

Further details related to country-based variations in diagnosis are provided in the report...

Lichen Planus Treatment

Cutaneous Lichen Planus typically clears spontaneously within 1 to 2 years, so treatment is aimed at reducing pruritus and time to resolution. For limited LP, first-line treatment is superpotent topical steroids (clobetasol 0.05%) twice daily for 2 to 4 weeks. Inadequate response to topical steroids may be augmented with intralesional steroid injections (triamcinolone 5 to 10 mg/mL). 

First-line treatment for oral Lichen Planus usually starts with high potency topical steroids three times daily until remission. In cases of no improvement after 6 weeks, second-line treatment is considered which includes oral corticosteroids or application of topical calcineurin inhibitors. Third-line treatment may include cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate.

The disease lacks FDA or EMA approved drugs for its treatment and the efficacy of the commonly administered treatments, i.e. topical and systemic steroids, steroid sparing agents, is only observed to be partial.

Lichen Planus Epidemiology

The Lichen Planus epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Lichen Planus  epidemiology is segmented with detailed insights into- Total Prevalent cases, Type-specific Cases, Gender-specific Cases, Age group-specific Prevalent Cases of Lichen Planus.

• The estimated global prevalence of oral Lichen Planus is about 2%. It is twice as common in women and is often diagnosed between the fifth and sixth decades of life, although it may also occur in children and young adults.
• As per DelveInsight's estimates, Lichen Planus usually appears in middle-aged adults from 30 to 60 years of age and rarely affects other age groups.

Lichen Planus Recent Developments

• In February 2025, Onc.AI announced that the FDA has granted Breakthrough Device Designation for its "Serial CTRS" AI model. This AI-driven tool uses deep learning to analyze CT scans and categorize patients into high- or low-mortality risk groups.
• In February 2025, Lipella Pharmaceuticals (Nasdaq: LIPO) announced FDA approval for an Expanded Access Program (EAP) for LP-310, an oral rinse aimed at treating oral Lichen Planus (OLP).

Lichen Planus Drug Chapters

The drug chapter segment of the Lichen Planus report encloses a detailed analysis of drugs. It also deep dives into the Lichen Planus clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. The Lichen Planus drugs market is witnessing growth due to rising awareness, improved diagnosis, and the development of innovative therapies targeting this chronic inflammatory skin condition to enhance patient outcomes globally.

Lichen Planus Emerging Drugs

LP-310: Lipella Therapeutics

Lipella was granted FDA approval to evaluate LP-310 in patients with oral Lichen Planus. LP-310 is an oral rinse formulation intended for the treatment of oral Lichen Planus, a chronic, painful, inflammatory, pre-malignant, T-cell-mediated, autoimmune disease affecting the oral mucosa of approximately 6-7 million Americans. There is no approved pharmacotherapy and most currently available treatments are palliative.

Lipella has received IND approval for a Phase IIa multicenter dose escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP. Lipella expects to commence dosing the first patient in the summer of 2024.

Patient recruitment is underway, and clinical testing of LP-310 is expected to commence in 2H 2024.

Note: Detailed emerging therapies assessment will be provided in the final report...

Lichen Planus Market Outlook

Lipella Therapeutics is evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Lichen Planus.

Key Findings

This section includes a glimpse of the Lichen Planus market in 7MM.

The United States Lichen Planus Market Outlook

This section provides the total Lichen Planus market size and market size by therapies in the United States.

EU-5 Countries Lichen Planus Market Outlook

The total Lichen Planus market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Lichen Planus Market Outlook

The total Lichen Planus market size and market size by therapies in Japan is also mentioned.

Lichen Planus Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Lichen Planus  Activities

The Lichen Planus pipeline report provides insights into different Lichen Planus clinical trials within various phases. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The Lichen Planus clinical trails analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Lichen Planus emerging therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Lichen Planus. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Market Access and Reimbursement

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Lichen Planus Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Lichen Planus, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Lichen Planus market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Lichen Planus market.

Lichen Planus Market Report Insights

• Lichen Planus Patient Population
• Lichen Planus Therapeutic Approaches
• Lichen Planus Pipeline Analysis
• Lichen Planus Market Size and Trends
• Existing and future Market Opportunity 

Lichen Planus Market Report Key Strengths

• Ten Years Forecast
• 7MM Coverage 
• Lichen Planus Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Lichen Planus Drugs Uptake
• Key Lichen Planus Market Forecast Assumptions

Lichen Planus Market Report Assessment

• Current Lichen Planus Treatment Practices
• Lichen Planus Unmet Needs
• Lichen Planus Pipeline Product Profiles
• Lichen Planus Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Lichen Planus Market Drivers
• Lichen Planus Market Barriers

FAQs

• What is the growth rate of the 7MM Lichen Planus treatment market?
• What was the Lichen Planus total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Lichen Planus? 
• How many Lichen Planus companies are developing therapies for the treatment of Lichen Planus?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to buy Lichen Planus Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Lichen Planus Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.